Bora Pharmaceuticals Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 08:01 pm
Share
Bora Pharmaceuticals Co., LTD. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 2,724.14 million compared to TWD 1,189.08 million a year ago. Net income was TWD 568.88 million compared to TWD 137.75 million a year ago. Basic earnings per share from continuing operations was TWD 5.8357 compared to TWD 1.4166 a year ago. Diluted earnings per share from continuing operations was TWD 5.8126 compared to TWD 1.4089 a year ago.
For the nine months, sales was TWD 5,196.02 million compared to TWD 3,750.18 million a year ago. Net income was TWD 988.05 million compared to TWD 609.69 million a year ago. Basic earnings per share from continuing operations was TWD 10.1239 compared to TWD 6.2976 a year ago. Diluted earnings per share from continuing operations was TWD 10.0854 compared to TWD 6.2822 a year ago.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
